Skip to content
BYO LUX
BYO LUXBe Your Own Luxury
All Treatments
Regenerative

LINERASE Injectable Type I Collagen

European injectable type I collagen biostimulator for scars, skin density, and regenerative aesthetics

Duration
20-40 min
Downtime
1-5 days
Sessions
3-4 sessions (2-4 wk intervals)

About This Treatment

LINERASE is a European injectable heterologous type I collagen product positioned within regenerative aesthetics. It is not primarily a contour-building filler like classic HA gels; instead, it is used as a collagen biostimulator aimed at atrophic acne scars, reduced skin density, fine lines, and lax-quality skin through fibroblast activation and extracellular-matrix remodeling.

Around 2025-2026, international aesthetics has continued shifting toward regenerative injectables beyond simple volumization, including PN, PDRN, PDLLA, PLLA, and collagen-focused approaches. Within that trend, LINERASE stands out because it is positioned as a medical injectable collagen product rather than a topical or supplement-style collagen concept. Because the category is newer and product handling matters, indication selection, source material, preparation, injection plane, and regional regulatory status all need careful verification.

Mechanism of Action

Micronized type I collagen is intended to act as a regenerative scaffold signal in the dermis to superficial soft tissue, promoting fibroblast activation, neocollagenesis, and extracellular-matrix remodeling. The product is not meant to create strong immediate projection; instead, it aims for gradual improvements in texture, density, and elasticity over weeks to months. Because it uses heterologous collagen, patient selection, product handling, and avoidance of superficial uneven deposition remain important.

Indications

AcneGeneral indication (see detailed description)Wrinkles / fine linesElasticity / firmness

Expected Results

In the product-specific prospective study, 30 patients with atrophic acne scars underwent four sessions at 2-week intervals. At 3 months, scar grades improved, physicians rated mean improvement at 6.8/10, patients at 7.2/10, and mean satisfaction at 7.4/10, with improvement sustained to 12 months. Expected changes are gradual rather than dramatic, focusing on scar smoothness, skin density, and overall textural refinement over a series of sessions.

Clinical Evidence

Product-specific / peer-reviewed
Gkouvi A, Tsiogka A, Corbo A, Tsimpidakis A, Gregoriou S (2025)
Efficacy of Heterologous Type I Collagen Injections in Treating Atrophic Acne Scars: A Prospective Study. Skin Appendage Disord
Clinical improvement was reported in this study (see original paper for details).
Indirect / ingredient class
Lombardi F, Palumbo P, Augello FR, et al. (2020)
Type I Collagen Suspension Induces Neocollagenesis and Myodifferentiation in Fibroblasts In Vitro. Biomed Res Int
Clinical improvement was reported in this study (see original paper for details).
Indirect / device class
Injectable collagen review authors (2023)
An Update on the Clinical Efficacy and Safety of Collagen Injectable Fillers. Polymers (Basel)
Clinical improvement was reported in this study (see original paper for details).
Manufacturer material
LINERASE (2025)
LINERASE Clinical & Scientific Studies / Product information. Manufacturer material
Clinical improvement was reported in this study (see original paper for details).

Risks & Side Effects

Swelling, redness, bruising, tenderness, papules, nodules, textural irregularity, infection, and asymmetry may occur. Because this is a heterologous collagen product, prior hypersensitivity history and informed consent require extra care. Superficial placement or excessive product can increase palpability and unevenness.

Interested in this treatment?

Start with an AI skin analysis to check your current skin condition

Get AI Skin AnalysisBook Now

Other Treatments

LaserPicoSure ProLearn more LaserFractional LaserLearn more LaserPhotofacial IPL (Stellar M22)Learn more Anti-AgingThermage FLXLearn more